Literature DB >> 2564453

Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase.

Y Kiriyama1, M Kubota, T Takimoto, T Kitoh, A Tanizawa, Y Akiyama, H Mikawa.   

Abstract

A human histiocytic lymphoma cell line, U937, is highly sensitive to L-asparaginase with an ID50 of about 0.0001 U/ml after 72 hr of culture. When U937 cells were made resistant to either L-asparaginase (1 U/ml) or asparagine deprivation, the activity of asparagine synthetase increased to 80- or 7-fold of the wild type, respectively. The phenotype of the resistance to L-asparaginase turned out to be stable under nonselective conditions for over several months. The hybrids between L-asparaginase sensitive (Molt4) and resistant (HL-60) cell lines revealed the latter phenotype in terms of L-asparaginase sensitivity and the activity of asparagine synthetase. Furthermore, U937 cells resistant to L-asparaginase could survive in glutamine-free media with 1.5-fold elevation of glutamine synthetase activity. These results altogether clarify the role of asparagine synthetase in L-asparaginase toxicity and have a good implication for the clinical use of L-asparaginase.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564453

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

1.  A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.

Authors:  S-H Chen; W Yang; Y Fan; G Stocco; K R Crews; J J Yang; S W Paugh; C-H Pui; W E Evans; M V Relling
Journal:  Leukemia       Date:  2010-11-12       Impact factor: 11.528

Review 2.  Asparagine synthetase chemotherapy.

Authors:  Nigel G J Richards; Michael S Kilberg
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

3.  An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line.

Authors:  Jemy A Gutierrez; Yuan-Xiang Pan; Lukasz Koroniak; Jun Hiratake; Michael S Kilberg; Nigel G J Richards
Journal:  Chem Biol       Date:  2006-12

Review 4.  Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.

Authors:  Xavier Thomas; Caroline Le Jeune
Journal:  Int J Hematol Oncol       Date:  2016-05-05

5.  Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells.

Authors:  A M Aslanian; B S Fletcher; M S Kilberg
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

6.  Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells.

Authors:  A M Aslanian; M S Kilberg
Journal:  Biochem J       Date:  2001-08-15       Impact factor: 3.857

7.  Asparagine synthetase is partially localized to the plasma membrane and upregulated by L-asparaginase in U937 cells.

Authors:  Yingyi He; Benshang Li; Changying Luo; Shuhong Shen; Jing Chen; Huiliang Xue; Jingyan Tang; Longjun Gu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-04-20

8.  Establishment of real-time polymerase chain reaction method for quantitative analysis of asparagine synthetase expression.

Authors:  Tamotsu Irino; Toshiyuki Kitoh; Kenichi Koami; Terumi Kashima; Kouichi Mukai; Eiji Takeuchi; Teruaki Hongo; Tatsutoshi Nakahata; Sheldon M Schuster; Mitsuhiko Osaka
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

9.  Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma.

Authors:  Gregory S Ducker; Jonathan M Ghergurovich; Nello Mainolfi; Vipin Suri; Stephanie K Jeong; Sophia Hsin-Jung Li; Adam Friedman; Mark G Manfredi; Zemer Gitai; Hahn Kim; Joshua D Rabinowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-09       Impact factor: 11.205

10.  First-line treatment of acute lymphoblastic leukemia with pegasparaginase.

Authors:  Riccardo Masetti; Andrea Pession
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.